- Browse
- Joseph Costello
- Bell et al
- pGL4.0-TERT WT
- Citations
pGL4.0-TERT WT Citations (9)
Originally described in: Cancer. The transcription factor GABP selectively binds and activates the mutant TERT promoter in cancer.Bell RJ, Rube HT, Kreig A, Mancini A, Fouse SD, Nagarajan RP, Choi S, Hong C, He D, Pekmezci M, Wiencke JK, Wrensch MR, Chang SM, Walsh KM, Myong S, Song JS, Costello JF Science. 2015 May 29;348(6238):1036-9. doi: 10.1126/science.aab0015. Epub 2015 May 14. PubMed Journal
Articles Citing pGL4.0-TERT WT
Showing 1 to 9 of 9 entries
| Articles |
|---|
Articles |
|---|
| The ERK inhibitor GDC-0994 selectively inhibits growth of BRAF mutant cancer cells. Chen Y, Sang Y, Li S, Xue J, Chen M, Hong S, Lv W, Sehgal K, Xiao H, Liu R. Transl Oncol. 2024 Jul;45:101991. doi: 10.1016/j.tranon.2024.101991. Epub 2024 May 9. PubMed |
| Telomere dysfunction promotes cholangiocyte senescence and biliary fibrosis in primary sclerosing cholangitis. Jalan-Sakrikar N, Anwar A, Yaqoob U, Gan C, Lagnado AB, Wixom AQ, Jurk D, Huebert RC. JCI Insight. 2023 Oct 23;8(20):e170320. doi: 10.1172/jci.insight.170320. PubMed |
| GABP couples oncogene signaling to telomere regulation in TERT promoter mutant cancer. McKinney AM, Mathur R, Stevers NO, Molinaro AM, Chang SM, Phillips JJ, Costello JF. Cell Rep. 2022 Sep 20;40(12):111344. doi: 10.1016/j.celrep.2022.111344. PubMed |
Conserved features of TERT promoter duplications reveal an activation mechanism that mimics hotspot mutations in cancer.
Barger CJ, Suwala AK, Soczek KM, Wang AS, Kim MY, Hong C, Doudna JA, Chang SM, Phillips JJ, Solomon DA, Costello JF.
Nat Commun. 2022 Sep 16;13(1):5430. doi: 10.1038/s41467-022-33099-x.
PubMed
Associated Plasmids |
| TERT Expression in Wilms Tumor Is Regulated by Promoter Mutation or Hypermethylation, WT1, and N-MYC. Jablonowski CM, Gil HJ, Pinto EM, Pichavaram P, Fleming AM, Clay MR, Hu D, Morton CL, Pruett-Miller SM, Hansen BS, Chen X, Jones KMD, Liu Y, Ma X, Yang J, Davidoff AM, Zambetti GP, Murphy AJ. Cancers (Basel). 2022 Mar 25;14(7). pii: cancers14071655. doi: 10.3390/cancers14071655. PubMed |
| Homeoprotein SIX1 compromises antitumor immunity through TGF-beta-mediated regulation of collagens. Liu W, Gao M, Li L, Chen Y, Fan H, Cai Q, Shi Y, Pan C, Liu J, Cheng LS, Yang H, Cheng G. Cell Mol Immunol. 2021 Dec;18(12):2660-2672. doi: 10.1038/s41423-021-00800-x. Epub 2021 Nov 15. PubMed |
| The ETS Inhibitor YK-4-279 Suppresses Thyroid Cancer Progression Independent of TERT Promoter Mutations. Xue J, Li S, Shi P, Chen M, Yu S, Hong S, Li Y, Liu R, Xiao H. Front Oncol. 2021 Jun 16;11:649323. doi: 10.3389/fonc.2021.649323. eCollection 2021. PubMed |
| Phase and context shape the function of composite oncogenic mutations. Gorelick AN, Sanchez-Rivera FJ, Cai Y, Bielski CM, Biederstedt E, Jonsson P, Richards AL, Vasan N, Penson AV, Friedman ND, Ho YJ, Baslan T, Bandlamudi C, Scaltriti M, Schultz N, Lowe SW, Reznik E, Taylor BS. Nature. 2020 Jun;582(7810):100-103. doi: 10.1038/s41586-020-2315-8. Epub 2020 May 27. PubMed |
| ARID1A-SIN3A drives retinoic acid-induced neuroblastoma differentiation by transcriptional repression of TERT. Bui CB, Le HK, Vu DM, Truong KD, Nguyen NM, Ho MAN, Truong DQ. Mol Carcinog. 2019 Nov;58(11):1998-2007. doi: 10.1002/mc.23091. Epub 2019 Jul 31. PubMed |
If you have published an article using this material, please email us at help@addgene.org to have your article added to this page.